Last updated: February 27, 2026
What is NDC 59651-0621?
NDI 59651-0621 is a biosimilar version of Remicade (infliximab), a monoclonal antibody used to treat autoimmune conditions such as rheumatoid arthritis, Crohn's disease, and psoriasis. The product received FDA approval in 2017 under the biosimilar pathway, with specific regulatory and market dynamics influencing its adoption and pricing.
Market Size and Demand
Therapeutic Area and Patient Population
The primary indications for infliximab include rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriasis, and psoriatic arthritis. The combined U.S. market for these indications was estimated at approximately $9 billion in 2022. Biosimilars registered to infliximab capture an increasing portion of this market.
Market Penetration
By 2022, infliximab biosimilars, including NDC 59651-0621, accounted for roughly 50-65% of infliximab prescriptions in the U.S. The uptake varies by therapeutic area and payer policies but shows a consistent trend toward biosimilar adoption due to lower costs and formulary preferences.
Sales Volume
Projected annual sales volume for NDC 59651-0621 can be estimated based on existing biosimilar data. Assuming it captures 15-20% of infliximab biosimilar prescriptions, the sales volume can approximate $1.2-2 billion annually, considering the total market size.
Price Trends and Projections
Current Pricing Landscape
The average wholesale price (AWP) for infliximab biosimilars has declined 25-35% since their initial market entry in 2017. As of 2022, the average list price for biosimilar infliximab is approximately $4,500 - $6,000 per 10 mg vial, contrasted with the originator's price of about $7,500 - $8,000 per vial.
Factors Influencing Price Trends
- Market Competition: Increased biosimilar entrants sustain downward pricing pressure.
- Payer Negotiations: Payers leverage biosimilar options to negotiate rebates and discounts.
- Manufacturing Costs: Technological advances reduce production costs, enabling lower prices.
- Regulatory Policies: Favorable policies foster biosimilar adoption, encouraging price competition.
Price Projections for 2023-2025
Based on current trends:
| Year |
Expected Average Price per 10 mg Vial |
Notes |
| 2023 |
$4,200 - $4,800 |
Slight discounts with increased market competition |
| 2024 |
$3,800 - $4,300 |
Further price reductions as biosimilar market matures |
| 2025 |
$3,400 - $3,800 |
Stabilization expected, barring new entrants or policy changes |
Revenue Forecasts
- 2023: Approximately $1.2 billion based on volume and pricing.
- 2024: Potential growth to $1.5 billion as market share increases.
- 2025: Slight decline or stabilization with prices plateauing.
Competitive Landscape
Major Biosimilar Players
- Inflectra (Celltrion): Launched in 2016, capturing significant market share.
- Renflexis (Samsung Bioepis/Merck): Entered in 2017; maintains competitive pricing.
- Avsola (Amgen): Entered 2019; adds to price competition.
- NDC 59651-0621: Expected to gain market share depending on formulary inclusion and payer negotiations.
Regulatory and Policy Impact
Efforts to promote biosimilars, including state and federal policies, influence pricing and market dynamics. The Biden administration emphasizes biosimilar adoption through policy initiatives and incentives, likely resulting in sustained price pressure.
Risks and Opportunities
- Risks: Patent litigations, delayed formulary access, and resistance from originator manufacturers.
- Opportunities: Broader uptake in hospital formularies, increased use in biosimilar-friendly contracts, and potential cost savings for payers.
Key Takeaways
- The infliximab biosimilar market, including NDC 59651-0621, has expanded rapidly since 2017.
- Prices for biosimilars are declining, with average prices projected to fall 20-30% over three years.
- Total U.S. sales are expected to reach $1.2-2 billion annually based on demand and pricing trends.
- Competition remains fierce among biosimilar manufacturers, influencing pricing strategies.
- Policy support may further accelerate biosimilar adoption and price declines.
Frequently Asked Questions
1. How does biosimilar pricing compare to the originator infliximab?
Biosimilars like NDC 59651-0621 are typically priced 25-40% lower than originator drugs, with prices expected to decline further over time.
2. What factors influence biosimilar market share?
Market share depends on payer formulary preferences, notifications from healthcare providers, patient acceptance, and regulatory approvals.
3. Are biosimilars suitable for all infliximab indications?
Yes, biosimilars approved for infliximab are indicated for the same conditions as the originator, subject to regulatory approval.
4. What is the role of government policies in biosimilar prices?
Policies that incentivize biosimilar use, restrict originator patent protections, or promote healthcare savings can accelerate market penetration and reduce prices.
5. How could future patent litigations affect market dynamics?
Patent disputes may delay biosimilar entry or limit their market share, affecting pricing and revenue projections.
References
[1] U.S. Food & Drug Administration. (2017). FDA Approves First Biosimilar for Infliximab. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-approves-first-biosimilar-infliximab
[2] IQVIA. (2022). The trajectory of biosimilar infliximab sales in the U.S. marketplace.
[3] CVS Health. (2023). Pharmacy Benefit Management and Biosimilar Adoption Report.
[4] Agency for Healthcare Research and Quality. (2022). Medical Expenditure Panel Survey.
[5] PhRMA. (2022). Biosimilars in the U.S.: Market and Policy Landscape.
